8-K: Current report filing
Published on December 23, 2015
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
December 21, 2015
NEOGENOMICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Nevada |
|
001-35756 |
|
74-2897368 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
|
|
|
|
12701 Commonwealth Drive, Suite 9, Fort Myers, Florida |
|
33913 |
|
(Address of principal executive offices) |
|
(Zip Code) |
(239) 768-0600
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
Item 5.07. |
Submission of Matters to a Vote of Security Holders. |
On December 21, 2015, NeoGenomics, Inc., a Nevada corporation (the “Company”), held a special meeting of its stockholders (the “Special Meeting”). At the Special Meeting, a total of 46,020,693 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), were present or represented by proxy at the meeting, representing approximately 76% of the outstanding Common Stock as of November 6, 2015, the record date for the special meeting. At the special meeting, six proposals were submitted for a vote of the Company’s stockholders and the related results are as follows:
|
|
(1) |
Proposal No. 1: The approval of the issuance of 15,000,000 shares of Common Stock and 14,666,667 shares of the Company’s Series A convertible preferred stock, as such number of shares may be adjusted as described in the proxy statement, to GE Medical Holding AB (“GE Medical”), pursuant to the Stock Purchase Agreement, dated October 20, 2015 (the “Purchase Agreement”), by and among the Company, NeoGenomics Laboratories, Inc. and GE Medical, pursuant to which the Company proposes to acquire from GE Medical all of the issued and outstanding shares of common stock of Clarient, Inc. (the “Transaction”). The stockholders approved the proposal by the following votes: |
|
|
|
Number of Votes |
|
Outstanding % |
|
Voted % |
|
|
For |
|
45,548,447 |
|
75.14% |
|
99.35% |
|
|
Against |
|
158,092 |
|
0.26% |
|
0.35% |
|
|
Abstentions |
|
138,429 |
|
0.23% |
|
0.30% |
|
|
|
|
Number of Votes |
|
Outstanding % |
|
Voted % |
|
|
For |
|
45,474,028 |
|
75.02% |
|
99.19% |
|
|
Against |
|
225,861 |
|
0.37% |
|
0.49% |
|
|
Abstentions |
|
145,080 |
|
0.24% |
|
0.32% |
|
|
|
Number of Votes |
|
Outstanding % |
|
Voted % |
|
|
|
For |
|
44,315,037 |
|
73.11% |
|
96.66% |
|
|
Against |
|
1,374,135 |
|
2.27% |
|
3.00% |
|
|
Abstentions |
|
155,796 |
|
0.25% |
|
0.34% |
|
|
|
(3) |
Proposal No. 3: The approval of an amendment to Article Fourth(A) of the Company’s Articles of Incorporation to increase the Company’s authorized shares of preferred stock by 40.0 million shares to an aggregate of 50.0 million shares. The stockholders approved the proposal by the following votes: |
|
|
(4) |
Proposal No. 4: The approval and adoption of the Purchase Agreement and the Transaction contemplated thereby. The stockholders approved the proposal by the following votes: |
|
|
|
Number of Votes |
|
Outstanding % |
|
Voted % |
|
|
For |
|
45,249,038 |
|
74.65% |
|
98.70% |
|
|
Against |
|
447,635 |
|
0.74% |
|
0.98% |
|
|
Abstentions |
|
148,295 |
|
0.24% |
|
0.32% |
|
(5) Proposal No. 5: The approval of an amendment and restatement of the Company’s Amended and Restated Equity Incentive Plan to increase the authorized number of shares of Common Stock available and reserved for issuance under the plan by 3.0 million shares to an aggregate of 12.5 million shares and to clarify provisions regarding restrictions on the repricing of options and stock appreciation rights. The stockholders approved the proposal by the following votes:
|
|
|
Number of Votes |
|
Outstanding % |
|
Voted % |
|
|
For |
|
42,837,306 |
|
70.67% |
|
93.44% |
|
|
Against |
|
2,822,156 |
|
4.66% |
|
6.16% |
|
|
Abstentions |
|
185,506 |
|
0.30% |
|
0.40% |
|
2
(6) Proposal No. 6: The approval to adjourn the special meeting, if necessary or appropriate, to solicit additional votes and proxies if there are insufficient votes at the time of the special meeting to approve the foregoing proposals. The stockholders approved the proposal by the following votes:
|
|
|
Number of Votes |
|
Outstanding % |
|
Voted % |
|
|
For |
|
43,277,473 |
|
71.39% |
|
94.04% |
|
|
Against |
|
2,116,840 |
|
3.49% |
|
4.60% |
|
|
Abstentions |
|
626,380 |
|
1.04% |
|
1.36% |
|
3
Item 8.01. Other Matters.
The investor presentation attached hereto as Exhibit 99.1 was presented to the Company’s stockholders at the special meeting.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
99.1 Special Investor Presentation of NeoGenomics, Inc. acquisition of Clarient, Inc. dated December 21, 2015
|
|
4
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
NEOGENOMICS, INC. |
|
|
|
|
|
By: |
|
/s/ George Cardoza |
|
|
|
George Cardoza |
|
|
|
Chief Financial Officer |
Date: December 23, 2015
5
Exhibit Index
Exhibit No. Description
|
99.1
|
Special Investor Presentation of NeoGenomics, Inc. acquisition of Clarient dated December 21, 2015
|
6